摘要滤泡性淋巴瘤（FL）是最常见的惰性非霍奇金淋巴瘤，与西方国家相比，中国的FL患者更年轻（发病中位年龄53岁），结外受累比例更高。尽管免疫治疗时代下FL患者的生存获得了提高，但是越来越多的证据显示FL是一组异质性疾病，其在诊断或治疗后2年内可出现疾病进展或复发，5年总生存率降至50%左右。因此，建立预后模型进行预后分层治疗及提高治疗效果是当前FL诊疗亟待解决的关键问题。本文梳理了近年来关于FL预后模型及治疗的研究成果，特别是2023年美国血液学会年会的重要进展，以期为临床医生提供最新的FL诊治思路。

abstractsFollicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Compared to Western countries, FL patients in China are younger (median age of onset: 53) and have a higher proportion of extra-nodal involvement. Despite improvement of survival in the era of immunotherapy for FL, increasing evidence shows that FL is a group of heterogeneous diseases, with a 5-year overall survival dropping to around 50% once disease progression/recurrence occurs within 2 years of diagnosis/treatment. Therefore, establishing prognostic models for stratified treatment and improving treatment effect is a key issue that urgently needs to be addressed. This article collected and summarized research findings on prognostic models and treatment for FL in recent years, particularly highlighting important advances since the 2023 American Society of Hematology Annual Meeting, providing clinicians with the latest approaches to the diagnosis and treatment of FL.